Text Size

Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity (no)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aydogan Aydogdu, Gulhane School of Medicine
ClinicalTrials.gov Identifier:
NCT01382576
First received: June 10, 2011
Last updated: March 9, 2012
Last verified: December 2010
History of Changes

June 10, 2011
March 9, 2012
January 2010
December 2010   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01382576 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity
Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity: A Pathophysiological Link Between Inflammation and Impaired Insulin Sensitivity?

In the present study, serum chitotriosidase activity and its relationship with insulin resistance were determined in patients with Polycystic Ovary Syndrome (PCOS).

ChT activity is increased in patients with PCOS in concordance with insulin resistance. These findings may reflect the pronounced risk for metabolic syndrome and atherosclerotic diseases in this particular patient group.
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   None Retained
Description:

No biospecimens were to be retained
Probability Sample

34 women with PCOS and 44 healty women as control group.
Polycystic Ovary Syndrome
Not Provided
  • PCOS patients
  • PCOS patients and healthy controls
    There are two groups in this study. One group is PCOS patients and other group is healthy controls.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
78
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Absence of significant abnormalities on physical examination except hirsutism
  • no lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy
  • normal thyroid function and prolactin level
  • absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic disease

Exclusion Criteria:

  • Pregnant
  • ovarian tumors
  • congenital adrenal hyperplasia or BMI greater than 30 kg/m2
Female
18 Years to 35 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT01382576
1491-81-11/1539-1563, Chitotriosidase activity
No
Aydogan Aydogdu, Gulhane School of Medicine
Gulhane School of Medicine
Not Provided
Principal Investigator: Aydogan Aydogdu, MD No organizational affiliation
Gulhane School of Medicine
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP